What the FDA labels say about taking them together
Cyclosporine and infliximab
Infliximab's FDA label of August 28, 2026 names cyclosporine in its drug interactions section; the cyclosporine labels PlainMeds reads (4) do not name infliximab. The infliximab label: “Upon initiation or discontinuation of AVSOLA in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration is recommended and the …”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the infliximab FDA label on DailyMed (effective August 28, 2026).
What does the cyclosporine label say about infliximab?
Cyclosporine's label (effective August 10, 2026) and its 3 other brand-application labels do not name infliximab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the infliximab label say about cyclosporine?
Infliximab label, drug interactionsUpon initiation or discontinuation of RENFLEXIS in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.
Source: FDA drug label (Inflectra, BLA125544), Pfizer Laboratories Div Pfizer Inc, effective July 28, 2026 (SPL set 37eaca10-d812-48bc-8b8e-b836bfa9968f), via openFDA
Source: FDA drug label (Avsola, BLA761086), Amgen, Inc, effective July 22, 2026 (SPL set de34bcb7-b524-45c8-9181-61c6f48d540e), via openFDA
Source: FDA drug label (Infliximab, BLA103772), Janssen Biotech, Inc., effective February 11, 2026 (SPL set b05c174f-832c-4321-b34f-2c4ad3742269), via openFDA
Source: FDA drug label (Renflexis), Organon LLC, effective August 28, 2026 (SPL set dbf738c4-3fac-4422-a9d8-51d9c83a8789), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Infliximab | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | Rheumatoid arthritis, Crohn's disease and ulcerative colitis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once